Skip to content

Author

Jeeyun Lee

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Oct 2026

Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy

Tovorafenib demonstrated single-agent clinical activity in solid tumors with BRAF fusions or CRAF fusions or amplification and had a manageable safety profile and may offer a new targeted treatment option for adult patients with tumors harboring these rare genomic driver alterations.

M. Vieito, E. Cabanas, I. Mehmi et al. · 0 citations
Open access Aug 2026

The Impact of Molecular Characteristics on the Efficacy of Frontline Immune Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma

Simple Summary Melanoma is a serious skin cancer, and in East Asian patients it frequently arises at acral sites or on internal mucosal surfaces rather than on sun-exposed skin. These forms tend to respond less well to immunotherapy, the current standard first-line treatment, yet it remains unclear which tumors benefit...

Seo Yoon Jang, Minsuk Kwon, Jeeyun Lee et al. · 0 citations
Open access Aug 2026

Genomic Landscape of Early-Onset Colorectal Cancer: A Comparative Analysis With Average-Onset Metastatic Colorectal Cancer in a Real-World NGS Cohort

In metastatic disease, EOCRC shares a conserved canonical genomic backbone with AOCRC, indicating that it is not a genomically distinct entity, which suggests that CRC arising at younger age may reflect distinct age-associated biological vulnerabilities.

J. Shin, Eunbyeol Lee, Yun-Ha Sang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.